[Translation] An open, multicenter phase IV clinical study on the efficacy and safety of different dosing regimens of decitabine for injection in the treatment of myelodysplastic syndrome (MDS)
To evaluate the efficacy and safety of decitabine for injection (50 mg) produced by Lianyungang Jereh Pharmaceuticals Co., Ltd. in the treatment of myelodysplastic syndrome (MDS) at different dosages/schemes, and to provide a basis for optimizing clinical dosing regimens.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.